Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Esophageal Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Anatomic Stage IV Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 16Cisplatin 11Radiotherapy 8Oxaliplatin 8Leucovorin 8Neoadjuvant Therapy 5Capecitabine 5Paclitaxel 4Nivolumab 4Docetaxel 4Trastuzumab 3Carboplatin 3dehydroftorafur 2Radiation 2Irinotecan 2Epirubicin 2Drug Therapy 2Chemotherapy, Adjuvant 2zolbetuximab 1zimberelimab 1zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1tislelizumab 1pertuzumab 1pembrolizumab 1gastrin immunogen 1Taxes 1Surgical Procedures, Operative 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma Of Esophagus × trastuzumab biosimilar HLX02 × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡